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Summary The expression of the ERG1, ERG3, ERG7, ERG9, ERG11 and ERG25 genes in response
to incubation with fluconazole and biofilm formation was investigated using reverse-
transcription PCR and real-time PCR in Candida albicans and Candida dubliniensis clinical
isolates. The viability of biofilm was measured using an 2,3-bis(2-methoxy-4-nitro-5-
sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay and confocal
scanning laser microscopy (CSLM). Expression of the ERG11 gene was found to be
low or moderate and it was regulated by fluconazole addition more so than by biofilm
formation. Very low or non-detectable expression of ERG1, ERG7 and ERG25 genes
was detected in C. albicans. The expression of the ERG9 increased in the presence of
fluconazole in some isolates. Following incubation with fluconazole, formation of
biofilm by C. dubliniensis was coupled with up-regulation of the ERG3 and ERG25
genes as have been observed previously in C. albicans. Planktonic cells of both Candida
species released from biofilm displayed similar resistance mechanisms to fluconazole
like attached cells. The XTT reduction assay and CSLM revealed that although
incubation with fluconazole decreased the biofilm thickness, these were still comprised
metabolically active cells able to disseminate and produce biofilm. Our data indicate
that biofilm represents a highly adapted community reflecting the individuality of
clinical isolates.
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Introduction
In the aetiology of disseminated infections, the forma-
tion of biofilms by pathogenic Candida species is often
critical.1–3 A wide range of biomaterials used in clinical
practice enables colonisation and subsequent forma-
tion of biofilm by Candida spp. Candida albicans is
predominantly isolated from clinical material related
to biofilm-associated infections.4–7 Candida dubliniensis is
phylogenetically closely related to C. albicans and these
two species share many virulence factors. Moreover,
both are able to form biofilms with similar structural
heterogeneity, typical microcolony and water channel
architecture.8,9
The process of biofilm formation by C. albicans
involves several steps. Chandra et al. described three
temporal developmental phases: early (0–11 h), inter-
mediate (12–30 h), and mature (38–72 h).10 Some
recent reports suggested the presence of possible fourth
dispersal stage that allows production and release of less
adherent daughter cells from mature biofilm.11,12
In general, biofilm-associated infections are frequently
refractory to conventional antibiotic therapy because of
increased resistance to antimicrobial agents.5,13–15 Can-
dida albicans biofilms have been shown to be resistant to a
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variety of azoles including fluconazole, voriconazole,
miconazole, itraconazole, ketoconazole, the antiseptic
chlorhexidine, antimetabolite drug flucytosine, and the
polyenes nystatin and amphotericin B.4,10,15–19 Resis-
tance to antifungals is predicted partially because of the
formation of a stratified biofilm and production of the
extracellular matrix that decrease the diffusion of anti-
fungals into the biofilm.20,21 Drug resistance occurring
during the initial stage of biofilm development ismediated
largely by the efflux pumps Mdr1, Cdr1 and Cdr2.22,23
The increase of drug resistance to fluconazole and
amphotericin B during biofilm maturation seems to be
associated with a significant decrease in the total ergos-
terol content as well as with changes in the abundance of
other sterols.23 This fact has been supported by observed
changes in the expression of some ERG genes involved in
ergosterol biosynthesis during maturation of biofilms in
comparisonwith planktonic cells.24 Themajor role in the
mentioned pathway is played by the enzyme cytochrome
P450 lanosterol 14a-demethylase (also referred to as
CYP51 and Erg11p) encoded by the ERG11 gene.25
Mutations or changes in ERG11 gene expression as well
as changes in other ERG genes such ERG1 (encodes
squalene epoxidase), ERG3 (encodes D5,6-desaturase),
ERG7 (encodes squalene cyclase), ERG9 (encodes squa-
lene synthase) or ERG25 (encodes C-4 methyl sterol
oxidase) play important role in the resistance of plank-
tonic cells to different antifungal agents.26–29 Although
there are many papers discussing the changes in cell
physiology and expression of different genes during
biofilm formation,24,26,30,31 ERG gene expression during
formation of biofilm exposed to azole derivatives has not
been investigated. Additionally, while previous studies of
biofilm development and resistance mechanisms have
been focused predominantly on C. albicans, relatively
little information is known concerning C. dubliniensis
biofilm formation.
The purpose of our study was to investigate the effect
of fluconazole on biofilm viability and to investigate the
potential role of changes in the expression of ERG genes
(ERG1, ERG3, ERG7, ERG9, ERG11 and ERG25) during
the early (1.5 and 6 h), intermediate (24 h) and mature
(48 h) phases of biofilm formation by C. albicans and
C. dubliniensis clinical isolates.
Materials and methods
C. albicans and C. dubliniensis clinical isolates
The three clinical C. albicans isolates (1395, 1173 and
47604, originated from Slovak hospitals) and one
C. dubliniensis clinical isolate (NIH 0492, kindly provided
by Prof. Y. Mikami) studied were recovered from
immunocompromised patients (stool samples from
patientswith allergy –C. albicans1395 and 1173,AIDS –
C. albicans 47604 and a blood sample from patient with
cancer – C. dubliniensis NIH 0492). The clinical isolates
were selected for their reduced susceptibility to fluco-
nazole (MIC95 > 64 mg l
)1).32 Fluconazole-susceptible
C. albicans SC531433 and C. dubliniensis CBS 7987
(Centraal Bureau voor Schimmelcultures, Delft, The
Netherlands) were used as reference strains. Isolates
were maintained in glycerol ⁄YPD (2% glucose, 1% yeast
extract, 2% bactopeptone) at )80 C.
Minimal inhibitory concentration (MIC) determinations
The MIC95 values (drug concentration that inhibited
growth by 95% compared with the growth of posi-
tive controls) for fluconazole (Pfizer, Zu¨rich, Switzer-
land) in tested strains were published previously
(MIC95 > 64 mg l
)1).32 The MIC95 for reference strains
C. albicans SC5314 and C. dubliniensis CBS 7987 were
determined by the broth microdilution method
according to the CLSI M27-A2 reference method in
RPMI 1640 medium [Applichem GmbH, Darmstadt,
Germany; buffered with 0.165mol l)1 3-(N-morpholino)
propanesulfonic acid, pH 7.0] in this work.34 The
0.5 · MIC95 values for fluconazole were used in
subsequent experiments. Strains were able to grow at
these concentrations without significant reduction
(they reached OD600 = 1 in overnight culture).
Preparation of yeast suspensions for the biofilm
formation
Yeast strains were cultivated on Sabouraud dextrose
agar (Biomark Laboratories, Puna, India) at 28 C for
24 h before use. For each strain, a large loop of cells
was transferred to the 200 ml of Yeast Nitrogen Base
broth (YNB) (Sigma-Aldrich, Taukirchen, Germany)
containing 0.9% of D-glucose and supplemented with
or without subinhibitory concentrations of fluconazole.
After overnight incubation at 37 C, the cells were
centrifuged and washed twice with 30 ml of phos-
phate-buffered saline (PBS), vortexed and centrifuged
at 5000 g for 5 min. The cells were then resuspended
in 50 ml of YNB broth containing 0.9% of D-glucose
and supplemented with or without subinhibitory
concentrations of fluconazole. Every sample was
adjusted to a final OD600 = 1.0 with YNB broth
supplemented with or without antifungal agent.
These cell suspensions were then used for biofilm
formation.
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The microtitre plate model of biofilm formation and the
effect of fluconazole on biofilm formation
A standardised method for biofilm formation using
polystyrene 96-well plates (flat bottom; DispoLab, Brno,
Czech Republic) was used.35 For biofilm growth, YNB
broth without ⁄with fluconazole was used. After 48-h
period, biofilm formation was quantified using the
2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazo-
lium-5-carboxanilide (XTT) reduction assay.35 The XTT
stock solution was prepared at 1 g l)1. A colorimetric
change was measured in a microplate reader (MRX
Microtitre plate absorbance reader; Dynex Technologies,
Chantilly, VA, USA) at 490 nm. Three repeats were
performed for each strain.
Slide model of biofilm formation for CSLM
Biofilms were formed on 25-mm diameter highly
adherent polyethylene coverslips (Sarstedt, Nu¨mbrecht,
Germany) as described previously.4 Coverslips were
immersed in 20 ml of a standardised cell suspension
(OD600 = 1.0) prepared as described above. Petri dishes
(Sarstedt) with prepared samples were incubated at
37 C for 90 min. After the adhesion period, superna-
tants including planktonic cells were discarded and Petri
dishes together with coverslips were washed twice with
20 ml of PBS. Twenty millilitres of fresh YNB broth
supplemented with or without subinhibitory concentra-
tions of fluconazole was added to each Petri dish and
incubated at 37 C for 48 h for biofilm growth. Follow-
ing biofilm formation, coverslips were gently washed
with PBS and used for confocal scanning laser
microscopy (CSLM).
Confocal scanning laser microscopy
Mature biofilms formed on polyethylene coverslips were
transferred to a new Petri dish and 20 ll of tetramethyl
rhodamine methyl ester, perchlorate (TMRM; Invitro-
gen, Carlsbad, CA, USA; excitation wavelength 549 nm,
emission wavelength 573 nm), diluted in distilled
deionised water to final concentration of 5 lmol l)1,
was applied onto each coverslip. Stained biofilms were
observed with a LSM 510 META confocal scanning laser
microscope mounted on Axiovert 200 M inverted
microscope (both from Carl Zeiss, Jena, Germany). A
543-nm line of He–Ne laser line for excitation, 545 nm
dichroic mirror and 565–615 nm band-pass emission
filter for fluorescence detection were employed. A
20 · ⁄ 0.75 PlanApochromat dry objective was used,
with the confocal pinhole opening of 1 airy unit. The
half-width of point-spread function in Z direction was
1.8–2 lm (in 500–600 nm wavelength range); there-
fore, we used 0.9 lm Z-axis sampling in three dimen-
sional data recording. For each image, 153 · 153 lm
area was scanned with resolution of 512 · 512 pixels,
16 · line averaging and 8-bit quantisation. Images
were further processed in the LSM IMAGE EXAMINER
software (Carl Zeiss). Biofilm images were either
displayed individually as 2-D plots or reconstructed in
three-dimensional (3-D) projections. Vertical (xz) sec-
tions or side views of the 3-D reconstructed images were
used to determine biofilm thickness and architecture.
The thickness was estimated from outer edges of the
area, where TMRM signal gain intensity was above half
of its maximum.
Preparation of biofilm in polystyrene Petri dishes for
qualitative sterol analysis, reverse-transcription PCR and
quantitative real-time PCR analysis
Modification of the standardised method for biofilm
formation in microtitre plate was used.35 For each
strain, 30 ml of the suspension (OD600 = 1.0) was
inoculated into four polystyrene Petri dishes (90-mm
diameter; Sarstedt). The plates were incubated at
37 C for 90 min to allow the adhesion of cells to
polystyrene surface. Planktonic cells from the first
Petri dish were collected, the adhered cells were
gently washed twice with 20 ml of sterile PBS and
both planktonic and adhered cells were used for RNA
isolation. Supernatants including planktonic cells and
liquid medium from the next three Petri dishes were
discarded and adhered cells were gently washed twice
with 20 ml of sterile PBS. For biofilm growth, 30 ml
of fresh YNB broth containing 0.9% of D-glucose
supplemented with or without fluconazole was added
to each Petri dish. The samples were cultivated for 6,
24 or 48 h at 37 C. At these time points, planktonic
cells were collected and formed biofilms were washed
with 20 ml of sterile PBS buffer. Biofilm cultures
formed in the Petri dishes were scraped using cell
scraper (Becton Dickinson, Le Pont-de-Claix, France),
resuspended in sterile PBS and directly used for
qualitative sterol analysis and RNA isolation or
flash-frozen in liquid nitrogen and stored at )80 C
until use.
Qualitative sterol analysis
Total sterols extracted from both planktonic cells and
biofilm were estimated using UV spectrophotometric
analysis as described by Moran et al. [36].
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Reverse transcription-PCR (RT-PCR) analysis
Genomic DNA was extracted from each isolate accord-
ing to Xu et al. [37]. RNA for RT-PCR analysis was
extracted from C. albicans and C. dubliniensis planktonic
cells and biofilm using RNeasy Mini Kit (Qiagen,
Hilden, Germany) according to the manufacturers
instructions. Aliquots of RNA (2 lg) were treated with
RNase-free DNase I (TaKaRa, Otsu, Japan) and stored at
)80 C until use. The TaqMan Reverse Transcription
Reagents (Applied Biosystems, Foster City, CA, USA)
were used to synthesise cDNA according to the man-
ufactures instructions. Random hexamers were used to
prime the cDNA synthesis reaction. Subsequent PCR
was performed with the primers amplifying genes ACT1,
ERG1, CaERG3, ERG7, ERG9, ERG11 and ERG25
according to Henry et al. [27]. The primer pair
CdERG3F-CdERG3R was derived from the primer
sequence used by Pinjon et al. [38]. A parallel reaction
with DNase treated RNA was performed to confirm that
the PCR product was derived from cDNA rather than
genomic DNA contamination. A reaction including
C. albicans or C. dubliniensis genomic DNA was used as a
positive control for the PCR reaction. PCR was per-
formed by initial denaturation at 94 C for 3 min,
followed by 28 cycles at 94 C for 1 min, 51 C for
1 min and 72 C for 1 min and a final extension at
72 C for 10 min. PCR products were analysed by 1.5%
agarose gel and visualised by ethidium bromide stain-
ing. Relative expression of individual genes was esti-
mated by comparison with ACT1 gene expression as
follows: weak expression (the intensity of respective
band was significantly lower than the intensity of those
of ACT1); m – moderate expression (comparable with
those of ACT1); s – strong expression (the intensity of
respective band was significantly stronger than the
intensity of those of ACT1).
Quantitative real-time PCR analysis
Real-time PCR was used for analysis of ERG1, ERG25
and TEF1 gene expression during biofilm formation in
C. albicans SC5314 and C. dubliniensis NIH 0492. RNA
was extracted from both planktonic cells and biofilm
using TRI-Reagent (Sigma-Aldrich) as described by
Stokes et al. [39].
Aliquots of RNA (500 ng) were treated with RNase-
free RQ1 DNase (Promega, Madison, WI, USA) and
cDNA was synthesised with Superscript II reverse
transcriptase (Gibco BRL Life Technologies, Rockville,
MD, USA) following the manufacturers instructions.
For an internal mRNA control and for detection of
genomic DNA, the primers specific for the EFB1 gene of
C. albicans, containing an intron of 365 bp were used
(Table 1).40 Furthermore, the absence of genomic DNA
contamination was also verified by performing PCR
amplification of RNA samples lacking reverse transcrip-
tase; so PCR products were not detected in these control
reactions. The control PCR was carried out using Go
Taq Flexi DNA polymerase (Promega).
Real-time PCR was carried out on an ABI Prism 7000
Sequence Detection system (Applied Biosystems) with
ABI PRISM 7000 SDS Software using 2 · QuantiTect SYBR
Green PCR Master Mix (Qiagen) as described by Moran
et al. [41].
The change in fluorescence of SYBR Green I dye in
every cycle was monitored by the software SEQUENCE
DETECTOR 1.7 provided with the ABI Prism 7700
system (Applied Biosystems) and the threshold cycle
(CT) above the background for each reaction was
calculated. For data analyses, CT values were exported
into a Microsoft Excel Worksheet for further statistical
analyses. The average CT value of housekeeping gene
(TEF1; gene for elongation factor 1-alpha)42 was
subtracted from the average CT value of tested genes
Table 1 Primers used for quantitative real-time PCR analysis
Gene Primer name GenBank accession no. Orientation1 Sequence (5¢ to 3¢) PCR amplicon size (bp)
EFB1 EF1F X96517 F ATTGAACGAATTCTTGGCTGAC cDNA-554
EF1R R CATCTTCTTCAACAGCAGCTTG DNA-919
TEF1 QRTTEF1F M29934 F CCACTGAAGTCAAGTCCGTTGA 51
QRTTEF1R R CACCTTCAGCCAATTGTTCGT
CaERG1 ERG1F U69674 F ACTAATGTTCCACCATTGGCTCT 84
ERG1R R CACATGACCTTTGCCCTTAGCT
CdERG12 CdERG1F U69674 F ACTAATGTTCCACCATTGGTTCT 84
CdERG1R R CACATGACCTTTGCCCTTGGCT
ERG25 ERG25F AF051914 F GCTCATCCAGTTGAAGTTGCC 82
ERG25R R GCAAGTTACCAGTGATAAGACACCA
1F = forward primer; R = reverse primer.
2The primer sequence for CdERG1 was based on the sequence for CaERG1 gene with simple nucleotide substitution.
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ERG1 and ERG25 to obtain a DCT value. The
comparative method (DDCT method) based on com-
paring differences in obtained DCT values was used
for manifestation of changes in the expression of
mentioned genes. The gene expression level relative
to the calibrator was expressed as 2–DDCT. Data for
each sample were obtained from three independent
experiments.
Results
Susceptibility testing, effect of fluconazole on formation
and structure of biofilm and qualitative sterol analysis
The reference strains C. albicans SC5314 and C. dublini-
ensis CBS 7987 were susceptible to fluconazole (MIC95 =
0.5 mg l)1 and MIC95 = 0.25 mg l
)1, respectively). On
the other hand, all clinical isolates exhibited decreased
susceptibility to this drug (MIC95 > 64 mg l
)1).32
The XTT reduction assay is the most commonly used
method for the determination of biofilm formation.
Using this as a marker for biofilm viability, it was
confirmed that the presence of fluconazole decreased the
ability to form biofilm in all tested C. albicans strains to
approximately one half (Fig. 1; P < 0.05). Similar
reduction was confirmed in C. dublininesis NIH 0492 (P
< 0.05). However, no significant effect of fluconazole on
biofilm formation was observed in C. dubliniensis CBS
7987 (P > 0.05).
The structure of mature biofilms formed by C. albi-
cans SC5314, C. albicans 1173, C. dubliniensis CBS
7987 and C. dubiniensis NIH 0492 was explored using
CSLM (Fig. 2). Biofilm formed by the fluconazole-
susceptible reference strain C. albicans SC5314 in the
absence of fluconazole revealed an approximately 9–
10 lm thick biofilm composed of both yeast and
hyphal cells. The presence of subinhibitory concentra-
tions of fluconazole decreased the thickness of biofilm
by less than half (4–5 lm; P < 0.05) and the mature
biofilm was composed exclusively of yeast cells. The
fluconazole-resistant clinical isolate C. albicans 1173
did not form the typical yeast–hyphal mixture in
biofilm using method described in Material and meth-
ods. The 15–16 lm thick biofilm found to be comprised
entirely of yeast cells, but following incubation with
fluconazole the biofilm biomass decreased dramatically
to negligible values and resulted in the formation of
yeast cell aggregated clusters. Biofilm formed by
fluconazole-susceptible reference strain C. dubliniensis
CBS 7987 as well as images of biofilm formed by the
fluconazole-resistant clinical isolate C. dubliniensis NIH
0492 showed biofilm formed by yeasts covered by
extracellular matrix. Incubation with fluconazole
caused splitting of the primary contiguous double layer
of yeast cells into aggregates formed by metabolically
active yeast cells. In a similar fashion to biofilms
formed by C. albicans, fluconazole decreased the thick-
ness of biofilms formed by C. dubliniensis CBS 7987
(from 15–16 to 8–9 lm; P < 0.05) and by
C. dubliniensis NIH 0492 (from 25 to 13–15 lm;
P < 0.05).
Qualitative analysis of total sterol contents revealed
no significant changes in ergosterol profiles during
Figure 1 Biofilm formation of Candida albicans 1395, C. albicans
1173, C. albicans 47604, Candida dubliniensis NIH0492 and
C. dubliniensis CBS 7987. The ability to produce biofilm without
presence of fluconazole (filled bars) and in the presence of
subinhibitory concentrations of fluconazole (hatched bars) was
quantified using the XTT-reduction assay. Values are mean of
triplicate determinations ± SD of the mean of biofilms formed in
96-well polystyrene microtitre plate.
(a)
(c)
(b)
(d)
Figure 2 Confocal scanning laser microscopy (CSLM) biofilm
images. A CSLM image of a biofilm produced by C. albicans SC5314
(a and b) and C. dubliniensis CBS 7987 (c and d) on polyethylene
coverslips after 48-h cultivation in the absence (a and c) or in the
presence of 0.5 · MIC95 of fluconazole in the medium (b and d).
Scale bar, 20 lm.
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formation of biofilm. The presence of ergosterol in both
C. albicans and C. dubliniensis was represented by four
peaks observed from the first stadium till maturation of
biofilm (Fig. 3).
RT-PCR and quantitative real-time PCR analysis
Reverse transcription-PCR was used for screening of the
expression of ERG genes (ERG1, ERG3, ERG7, ERG9,
ERG11 and ERG25) involved in the ergosterol biosyn-
thesis pathway of C. albicans and C. dubliniensis during
biofilm formation (at 1.5, 6, 24 and 48 h). The
expression of individual genes was estimated by com-
parison with that shown by the ACT1 gene (Table 2 and
Fig. 4). Results summarised in Table 2 showed that the
expression of ERG1, ERG7 and ERG25 genes in
C. albicans was observed to be very weak or not
detectable with the addition of fluconazole having little
or no effect on the expression of these genes. The
expression of the ERG3, ERG9 and ERG11 genes in
C. albicans varied according to isolate tested. The
expression of ERG3 gene was influenced rather by
biofilm formation than fluconazole addition. On the
other hand, the presence of fluconazole up-regulated
expression of the ERG9 gene regardless of susceptibility
of tested strains. In the fluconazole sensitive reference
strain C. albicans SC5314, the expression of ERG11 was
found to decrease after incubation with fluconazole, in
opposite to fluconazole-resistant isolates C. albicans
1173 and C. albicans 47604, where incubation with
fluconazole increased expression of this gene. Similarly
to results obtained in C. albicans strains, the expression
of both ERG1 and ERG7 genes was not observed in
C. dubliniensis. On the other hand, expression of other
tested genes in C. dubliniensis was different from those
observed in C. albicans strains. In fluconazole-resistant
C. dubliniensis NIH 0492, incubation with fluconazole
up-regulated the expression of the genes ERG25, ERG3
and ERG11. Moreover, strong up-regulation of the
ERG3 gene affected by fluconazole was found also in
fluconazole-sensitive C. dubliniensis strain CBS 7987. On
the other hand, no expression of the gene ERG11 was
detected in this strain. The expression of the ERG9 gene
in both C. dubliniensis isolates tested was weak or
moderate and minimally affected by fluconazole. Mat-
uration of biofilm was associated with slightly increased
ERG11 expression, more significant in fluconazole-
resistant C. albicans isolates than in fluconazole-resis-
tant C. dubliniensis.
Based on these results, C. albicans SC5314 and
C. dubliniensis NIH 0492 were selected for detailed
analysis of ERG1 and ERG25 gene expression using
quantitative real-time PCR analysis.
In C. albicans strain SC5314, the addition of fluco-
nazole to the medium slightly increased the expression
of ERG1 gene in both planktonic cell population
(1.29 ± 0.26 times) and cells forming biofilm
(1.27 ± 0.30 times) in comparison with the drug free
controls. For clinical isolate C. dubliniensis NIH 0492,
no amplification of ERG1 was detected as observed
previously by RT-PCR. Subinhibitory concentrations of
fluconazole increased the expression of ERG25 gene in
Figure 3 UV spectrophotometric profiles of non-saponifiable lipids from C. albicans reference strain SC5314, C. dubliniensis reference strain
CBS 7987 and C. albicans clinical isolate 1395 and C. dubliniensis clinical isolate NIH 0492 with reduced susceptibility to fluconazole
(MIC95 > 64 mg l
)1). Sterols were extracted from three biofilm developmental stages: early (1.5 and 6 h), intermediate (24 h), and mature
(48 h) as described in Materials and methods.
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C. albicans SC5314 planktonic cells (3.13 ± 0.19
times) and in biofilm (1.65 ± 0.3 times) in comparison
with the drug free control. Candida dubliniensis NIH
0492 planktonic cells and biofilm showed the highest
degree of up-regulation of the ERG25 gene following
exposure to fluconazole in comparison with the drug
free controls (3.98 ± 0.15 and 29.77 ± 0.24 times,
respectively). The expression of the tested genes in both
C. albicans and C. dubliniensis indicated no significant
changes because of formation of biofilm with the
exception for C. dubliniensis NIH 0492, where the
expression of ERG25 gene increased 1.68 ± 0.5 times
in later stages (at 48 h) of biofilm formation in
comparison with that observed in the first stage (at
1.5 h).
Parallel analysis focused on the expression of ERG
genes tested was performed by both methods using
planktonic cells. Planktonic cells represented non-
attached cells that are released from biofilm during its
formation. These cells were collected parallel with biofilm
at four time point (at 1.5, 6, 24 and 48 h). The RT-PCR
revealed that planktonic cells displayed similar ERG gene
expression profiles to those observed for biofilm (data not
shown). Although using RT-PCR, we did not detect any
expression of the ERG25 gene in C. albicans SC5314, the
Table 2 Detection of reverse-transcription PCR (RT-PCR) products during the biofilm formation in Candida albicans and Candida dubliniensis
Strain Time (h)
Genes
ERG1 ERG3 ERG7 ERG9 ERG11 ERG25
) ⁄ + FLC ) ⁄ + FLC ) ⁄ + FLC ) ⁄ + FLC ) ⁄ + FLC ) ⁄ + FLC
Candida albicans SC5314 1.5 ND ⁄ w ND ⁄m ND ⁄ w m ⁄m w ⁄ w ND ⁄ w
6 ND ⁄ w w ⁄ w w ⁄ w m ⁄m m ⁄ w ND ⁄ w
24 ND ⁄ w m ⁄m w ⁄ w m ⁄m m ⁄ w ND ⁄ w
48 ND ⁄ ND m ⁄m w ⁄ w m ⁄ s m ⁄ w ND ⁄ w
Candida albicans 1395 1.5 w ⁄ ND w ⁄ w w ⁄ ND m ⁄ s ND ⁄ ND w ⁄ w
6 w ⁄ ND m ⁄ w w ⁄ ND m ⁄m ND ⁄ ND w ⁄ w
24 w ⁄ ND m ⁄ w w ⁄ ND m ⁄m w ⁄ w w ⁄ w
48 w ⁄ w m ⁄m w ⁄ ND m ⁄ s w ⁄ w w ⁄ w
Candida albicans 1173 1.5 ND ⁄ ND ND ⁄ w ND ⁄ ND w ⁄ s ND ⁄m ND ⁄ ND
6 ND ⁄ ND ND ⁄ w ND ⁄ ND m ⁄ s ND ⁄m ND ⁄ ND
24 ND ⁄ ND w ⁄ w ND ⁄ ND m ⁄m ND ⁄ w ND ⁄ ND
48 ND ⁄ ND m ⁄ w w ⁄ ND m ⁄m m ⁄ w ND ⁄ ND
Candida albicans 47604 1.5 w ⁄ ND w ⁄ w w ⁄ ND m ⁄m w ⁄ ND ND ⁄ ND
6 w ⁄ ND m ⁄ w w ⁄ ND m ⁄ s w ⁄ w w ⁄ ND
24 w ⁄ ND w ⁄ w ND ⁄ ND m ⁄ s w ⁄ m w ⁄ ND
48 w ⁄ ND w ⁄ w ND ⁄ ND m ⁄ s w ⁄ m w ⁄ ND
Candida dubliniensis CBS 7987 1.5 ND ⁄ ND m ⁄ s ND ⁄ ND m ⁄ w ND ⁄ ND ND ⁄ w
6 ND ⁄ ND m ⁄ s ND ⁄ ND m ⁄ w ND ⁄ ND ND ⁄ w
24 ND ⁄ ND m ⁄ s ND ⁄ ND m ⁄ w ND ⁄ ND ND ⁄ w
48 ND ⁄ ND m ⁄ s ND ⁄ ND w ⁄ w ND ⁄ ND ND ⁄ w
Candida dubliniensis NIH 0492 1.5 ND ⁄ ND m ⁄ s ND ⁄ ND w ⁄ m ND ⁄ w ND ⁄m
6 ND ⁄ ND m ⁄ s ND ⁄ ND m ⁄m ND ⁄ w ND ⁄ s
24 ND ⁄ ND m ⁄ s ND ⁄ ND m ⁄m ND ⁄ w w ⁄ s
48 ND ⁄ ND s ⁄ s ND ⁄ ND m ⁄m w ⁄ w w ⁄ s
Biofilm was produced in medium supplemented without ()) ⁄ with (+) fluconazole. Relative expression of individual genes was estimated by
comparison with ACT1 gene expression: ND, not detectable; w, weak expression; m, moderate expression, comparable to those of ACT1; s,
strong expression; FLC, fluconazole. Data for expressions of individual genes were obtained from two independent experiments.
Figure 4 Representative picture of reverse-transcription PCR
(RT-PCR) analysis of C. albicans SC5314 and C. dubliniensis NIH
0492. RT-PCR was used to analyse the relative expression of
ACT1, ERG1 and ERG25 genes in three biofilm developmental
stages: early (1.5 and 6 h), intermediate (24 h) and mature
(48 h). Equal volumes of DNase treated RNA with primers for
actin were amplified in parallel to detect genomic DNA
contamination (ACT1-N). Following PCR reaction, PCR products
were analysed by 1.5% agarose gel and visualised by ethidium
bromide staining. Samples were cultivated in Yeast Nitrogen
Base broth containing 0.9% of D-glucose and supplemented with
(+) or without ()) fluconazole.
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higher sensitivity of quantitative real-time PCR analysis
revealed that planktonic cells without addition of fluco-
nazole exhibited higher expression of the ERG25 gene in
both C. albicans SC5314 (6.56 ± 0.38 times) and C. dub-
liniensis NIH 0492 (5.01 ± 0.5 times) strains in compar-
ison with that observed in biofilm cells.
Discussion
Candida spp. can adhere and form biofilm on the surfaces
of a wide range of medical devices resulting in reduced
susceptibility to antimicrobial agents.1,2,21,43 Candida
albicans-like bacterial biofilm-associated resistance has
been explained because of multiple mechanisms includ-
ing drug efflux pumps, extracellular matrix production,
decrease of cellmetabolismandunique architecture.44–46
The treatment of C. albicans biofilm by antifungals is
accompanied by the changes in morphology of biofilm.
CSLM in conjunction with labelling by TMRM allowed
observation of intact structures containing living cells
during biofilm formation. The morphology of biofilm
showed to be surface pattern dependent as was already
described by Chandra et al. [10]. They showed that
irregular surface of polymethylmethacrylate allows
formation of only 25–30 lm thick biofilm formed
mainly by yeast cells. On the other hand, C. albicans
cells growing on silicone elastomer produce a nearly
uniform layer of adherent blastospores, which at mat-
uration are approximately 10–12 lm thick and above
this layer is a profuse matrix (at least 450 lm thick)
consisting of extracellular material and hyphal ele-
ments. The proportions of yeast and hyphal forms
depend also on medium flow, aeration, temperature and
incubation time.24 In our study, we used polyethylene
coverslips and polystyrene Petri dishes for biofilm
formation. Both materials are hydrophobic and allow
strong attachment of Candida cells to the surface, which
is an important step in biofilm formation. Although
polystyrene plate is made from material different from
that used for intravenous catheters, the adhesion
properties of both materials are similar. This is a reason
why a standardised method for biofilm formation
employing polystyrene 96-well plates is generally
accepted by many authors.18 On the other hand, the
advantage of polyethylene coverslips for CSLM is easy
manipulation and application of this material in in vivo
models.43,44 Nobile et al. [47] successfully used the
polyethylene catheter in an in vivo rat model for biofilm
formation. However, polyethylene did not induce the
formation of typical yeast-hyphae structure of mature
biofilm in all tested strains. In spite of this limitation, the
effect of subinhibitory concentrations of fluconazole was
notable in all tested strains without any relation to
fluconazole susceptibility or resistance. The biofilm
thickness as well as density of yeast cell layer was
affected. Moreover, fluconazole influenced the property
of strain C. albicans SC5314 to form hyphae. The
morphology of studied biofilms was confirmed by light
microscopy of biofilms formed in polystyrene Petri
dishes (pictures not shown). Similar observation in
fluconazole efficiency on biofilm was published by
Bruzual et al. [48], who reported inhibition of C. albicans
biofilm in the presence of fluconazole in the medium
regardless of susceptibility of tested strains.
Two major resistance mechanisms have been identi-
fied in C. albicans and C. dubliniensis; expression of
multidrug transporters that reduce the drug accumula-
tion22,23,30,49–52 and alteration of membrane sterol
composition represented mainly by changes in ergos-
terol biosynthesis pathway.23,26,28,38,53,54
We investigated the expression of ERG genes (ERG1,
ERG3, ERG7, ERG9, ERG11 and ERG25) employing
RT-PCR and real-time PCR in C. albicans and C. dublin-
iensis in response to incubation with fluconazole and
biofilm formation. Three of the genes examined (ERG9,
ERG1 and ERG7) encode enzymes that act upstream
and two (ERG25 and ERG3) encode enzymes that act
downstream of lanosterol demethylase in the ergosterol
biosynthesis pathway. The C. albicans and C. dubliniensis
clinical isolates were selected for their reduced suscep-
tibility to fluconazole (MIC95 > 64 lg ml
)1) and high
ability to form biofilm in comparison with standard
strain C. albicans SC5314.
Up-regulation of C. albicans ERG11 or C. dubliniensis
ERG11 genes encoding the target enzyme Erg11p for
azole antifungal drugs often results in resistance to azole
derivatives.38,52 Henry et al. [27] reported that cultiva-
tion in the presence of azole drugs increased the
expression of ERG11 gene in planktonic cells, but this
induction has not been observed during biofilm forma-
tion in standard strains C. albicans SC5314 and C. albi-
cans CA-1.24,26 We obtained similar results with
C. albicans SC5314, but tested clinical isolates reflected
variability among strains. The expression of ERG11
gene was proved low or moderate in comparison with
ACT1 gene and it was influenced by fluconazole addition
rather than by biofilm formation. It is of interest that in
both C. dubliniensis isolates, lower expression of the
ERG11 gene was coupled with an increased level of
ERG3 mRNA. A similar effect was observed in fluco-
nazole resistant mutants of C. glabrata.55 Moreover,
the presence of fluconazole strongly influenced the
expression of the ERG3 gene in fluconazole resistant
C. dubliniensis NIH 0492.
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The main difference in the expression of ERG genes
between C. albicans and C. dubliniensis was observed in
the ERG25 gene expression. Strong up-regulation of this
gene following fluconazole addition was obtained in
clinical isolate C. dubliniensis NIH 0492. A real-time PCR
analysis was in agreement with results from RT-PCR.
During biofilm formation, the expression of ERG25 gene
increased, after 48-h biofilm formation, 2.7 times in
C. dubliniensis NIH 0492 unlike to in C. albicans SC5314
in which there was no increase. The up-regulation of
ERG25 and also ERG2, ERG7 and ERG11 in C. albicans
following azole treatment has been previously shown to
be induced by the transcription factor encoded by the
UPC2 gene. This regulator controls sterol uptake under
anaerobic conditions which are encountered in the
mature biofilm formed static in a microtitre plate.24,56
The role of UPC2 gene in C. dubliniensis remains to be
further investigated. Moreover, the real-time PCR anal-
ysis revealed no expression ofERG1 gene inC. dubliniensis
NIH 0492 in contrast to C. albicans SC5314 exhibiting
slight expression of this gene. A significantly reduced
expression ofERG1 gene in the blastospore subpopulation
in C. albicans biofilms resistant to amphotericin B has
already been reported by Khot et al. [26]. Such global up-
regulation of multiple genes involved in the ergosterol
biosynthetic pathway can shuttle non-ergosterol inter-
mediates into the membrane.54
Mukherjee et al. [23] in their work revealed by
quantitative sterol analysis that total ergosterol level
significantly decreased at later stages of biofilm forma-
tion in comparison with planktonic cells. Using quali-
tative sterol analysis in our work, we did not confirm
the presented data and we did not observe changes in
total sterol profile including ergosterol during formation
of biofilm in all tested isolates. On the basis of that
information, we hypothesise that mature biofilm com-
munities may represent hypoxic microenvironments
with negative effect on the synthesis of new free
ergosterol, but with no significant effect on total
ergosterol contents as described by Shobayashi et al.
[57] in Saccharomyces cerevisiae laboratory strain
X2180-1A.
The comparison of the expression of genes in biofilm
and planktonic cells released from the biofilm did not
show significant differences and the up-regulation of
some ERG genes in individual C. albicans and C. dublin-
iensis strains correlated with that described for biofilm.
Such cells could represent the dispersal stage of biofilm
capable of spreading Candida infection.11,12
Our data suggest that the degree of biofilm formation by
clinical isolates is strain-dependent. Previous published
information about increased expression of ERG3 and
ERG25 genes in C. albicans during biofim formation was
also confirmed in fluconazole-resistant C. dubliniensis.
Planktonic cells released from biofilm displayed similar
mechanisms of resistance to fluconazole as the attached
cells. On the other hand, CSLM revealed that although
incubation with fluconazole decreased the biofilm thick-
ness and yeast cells aggregated to clusters, these were still
formed by metabolically active cells able to disseminate
and produce biofilm. This can explain frequent relapses of
candidiasis in immunocompromised patientswho require
prophylactic antifungal therapy. Understanding of the
role of different C. albicans and C. dubliniensis genes in
biofilm formation and resistance to antifungal
agents could ultimately be helpful for control of
Candida infections associated with using artificial medical
devices.
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